市场调查报告书
商品编码
1258862
到 2028 年的饲料抗球虫药市场预测——按类型、牲畜、消费模式、形式、来源和地区进行的全球分析Feed Anticoccidials Market Forecasts to 2028 - Global Analysis By Type, Livestock, Mode of Consumption, Form, Source and By Geography |
据Stratistics MRC预测,2022年全球饲料抗球虫剂市场规模将达到3.7218亿美元,预计2028年将达到5.3396亿美元,预计将以6.2的CAGR增长% 期间。
饲料抗球虫剂常用作饲料和兽药添加剂,用于治疗家禽和其他动物的球虫感染。 这些是由白色链霉菌产生的活性物质。 它是一种聚醚离子载体抗生素。 球虫病是一种同时感染家畜和野生动物的肠道传染病,球虫病是畜牧业重大经济损失的罪魁祸首。
根据畜牧业和乳业部的数据,在印度,鸡肉行业贡献了 75.32%,鸡蛋行业贡献了 24.67%。 此外,2018-2019 年的年鸡肉产量为 4.06 公吨。
人们的饮食和消费模式发生了很多变化,越来越多的人吃鸡肉。 政府还开展各种活动,以提高公众对动物健康价值的认识。 动物饲料中使用的抗球虫剂引起了人们的关注,因为它们对于维持动物免疫力和肠道环境至关重要。 对副作用较少的天然动物饲料添加剂的需求越来越大。 因此,需求正在增加,尤其是家禽生产商。 由于与动物产品消费相关的慢性病患病率上升,用于动物饲料的抗球虫剂市场正在增长。
由于出现了对用于治疗人类和动物感染的抗生素具有耐药性的微生物,欧盟于 2006 年禁止使用抗生素作为生长促进剂。 自欧盟取消抗生素使用禁令以来,世界上许多国家,尤其是中国、印度和美国,抗生素的使用都出现了下降。 因此,受影响国家的这些抗生素治疗收入大幅下降。
饲料抗球虫病的一个主要驱动因素是家禽中球虫病发病率的上升。 据说鸡等鸟类易患球虫病,这是一种引起肠道疾病的寄生性原生动物疾病。 近年来,球虫病变得非常普遍。 对药物治疗具有抗性的新寄生虫菌株的出现与这一趋势一致。 此外,新型优质原材料的开发和新兴市场的出现,将在预测期内为饲料抗球虫剂市场创造更多有利可图和回报丰厚的增长机会。
对各种艾美球虫药物的耐药性和消费者购买不含药物的家禽产品的压力是在家禽中使用抗球虫药的两个主要缺点。 在此背景下,研究开始寻找安全的替代品。 大多数这些研究的共同目标是找到含有能有效防止艾美球虫生长的化合物的植物。 已被评估为具有抗球虫活性的草药已成为文献研究的主题,并且是其提取物。 这些结果可能会限制近期的市场扩张。
最初的 COVID-19 封锁影响了全球家禽饲料供应并扰乱了物流系统。 最初,世界各地的家禽饲料企业受到监管或关闭,造成畜牧业者饲料短缺。 除了大规模生产停工和供应链中断外,许多製造商还因劳动力短缺而关闭运营,因此食品供应也出现短缺。 由于对 COVID-19 病毒的恐惧以及封锁使人们无法离开家园,高度依赖自製素食是导致大流行期间饲料抗球虫药销量下降的其他因素。一些。
由于球虫的存在,家禽中常见的寄生虫病是使用抗生素。 因此,预计家禽业在预测期内将占据最大份额。 由于与球虫同居,感染在肠道中发展。 球虫中毒会对家禽产生重大的负面影响,并在经济上扰乱家禽业。 因此,适当的管理对于预防球虫中毒极为重要。 预防家禽球虫病的一个主要要求是疫苗接种运动和在预防和治疗中使用抗球虫药。
在预测期内,盐霉素部分有望实现良好增长。 Salinomycin 是一种单羧酸聚醚抗生素,由白色链霉菌在发酵过程中产生。 盐霉素的主要作用机制涉及其亲离子活性,主要通过与以復杂方式进入牲畜细胞的钾、钠、铷和锂等单价阳离子结合。 与其他抗球虫药相比,它们的低成本和现成的可用性使其成为全球增长最快的细分市场。
由于牲畜数量庞大,预计亚太地区在预测期内将占最大份额。 由于医疗保健成本上升(尤其是在印度和中国)以及过去几年人们对动物健康意识的增强等因素,亚太地区兽医保健市场经历了重大变革。 中国和印度的肉类和家禽生产畜牧业也显着增加。 畜牧生产者专注于动物保健,并过度使用抗球虫剂等牲畜抗生素来满足对牛奶和肉类产品不断增长的需求。 这些因素正在加速该行业的发展。
预计在预测期内,北美的增长率最高。 该部门的市场需求是由确保家禽产品质量和提高生产率的日益增长的需求驱动的。 此外,政府加大对製药企业的投资也在扩大市场需求。 在美国之后,加拿大拥有最大的市场份额。 推动该国市场的因素之一是饲养牲畜数量的增加。 据信,对优质肉类产品的需求不断增长正在加速该地区的市场增长速度。
饲料抗结块市场的主要参与者是Bioproperties Pty.Ltd.、Ceva Animal Health、Elanco Animal Health、Huvepharma、Impextraco、Kemin Industries、Merck Animal Health、Phibro Animal Health、 Qilu Animal Health Products Co. Ltd.、Virbac S.A、Zydus Animal Health 和 Zoetis。
2023 年 2 月,Elanco Animal Health 宣布增加 PenPoint(TM) Sort,以最大限度地提高养牛者的盈利能力。 PenPoint Sort 增加了现有的 Elanco 知识解决方案服务组合,旨在通过支持数据驱动决策制定的可信工具、技术和洞察力优化运营和产品。
2023 年 2 月,Elanco Animal Health 宣布 Bexacat□(贝格列净片剂)获得美国食品和药物管理局 (FDA) 的批准,这是第一种改善糖尿病猫血糖控制的口服处方药。 这扩大了 Elanco 的创新猫产品组合,并解决了成年猫对这种慢性疾病未得到满足的需求。
2022 年 12 月,Ceva Sante Animale 宣布收购专门从事动物保健产品製造和分销的阿根廷公司 Zoovet,以及开发由 Zoovet 营销的创新产品的生物技术初创公司 Biotecnofe。
购买此报告的客户将免费获得以下定制之一。
According to Stratistics MRC, the Global Feed Anticoccidials Market is accounted for $372.18 million in 2022 and is expected to reach $533.96 million by 2028 growing at a CAGR of 6.2% during the forecast period. Feed anticoccidials are commonly used as an additive in feed and veterinary medications and are used to treat coccidial infections in poultry and other animals. These are substances that are active and made by the bacteria Streptomyces albus. They are polyether ionophore antibiotics. Since coccidiosis is an infectious disease of the intestinal tract that affects both domestic and wild animals, the coccidia are to blame for significant financial losses to the livestock industry.
According to Depart of Animal Husbandry and Dairying, contribution from poultry meat sector was contributed to be 75.32% and poultry egg sector contributed to be 24.67% in India. In addition, the annual production of poultry meat was 4.06 metric tons in the year 2018-2019.
There have been numerous changes in the population's dietary habits and consumption patterns, which have led to a shift towards more people eating poultry. In addition, the government launches a number of campaigns to raise public awareness of the value of animal health. Anticoccidials used in animal feed have drawn a lot of attention because they are essential for maintaining the immunity and gut health of animals. Natural animal feed additives with minimal side effects are becoming more and more in demand. Due to this, demand has increased, primarily among producers of poultry. The market for animal feed anticoccidials is consequently growing due to the rising prevalence of chronic diseases linked to the consumption of animal byproducts.
Due to the emergence of microorganisms that are resistant to antibiotics used to treat human and animal infections, the European Union banned the use of antibiotics as growth promoters in 2006. In many nations around the world, especially in places like China, India, and the United States, the use of antibiotic remedies has decreased since the European Union's ban on their use was lifted. This caused a sizable loss in revenue for these antibiotic treatments in the affected nations.
The primary driver of feed anticoccidial is the rising incidence of coccidiosis in poultry. Chickens and other birds are susceptible to the parasitic protozoa disease coccidiosis, which causes intestinal illness. Coccidiosis has become much more commonplace in recent years. The emergence of new parasite strains that are more resilient to drug treatment coincides with this trend. Additionally, during the forecast period, the development of high-quality and new raw materials as well as emerging new markets will further create lucrative and rewarding growth opportunities for the feed anticoccidials market.
The resistance of various Eimeria spp. to drugs and consumer pressure to buy poultry products free of drug residues were the two main drawbacks to using coccidiostats in poultry. This circumstance served as a catalyst for research into finding secure alternatives. Finding plants with compounds that are effective at preventing Eimeria spp. from multiplying was the common goal of the majority of these studies. The evaluated herbs with anticoccidial properties have been the subject of documented studies and their extracts. These outcomes may limit market expansion in the near future.
The initial COVID-19 lockdown affected the global supply of poultry feed and disrupted the logistics system. In the beginning, there had been restrictions and closures of poultry feed businesses all over the world, which led to a shortage of feed for livestock farmers. The supply of food products was insufficient as many of the manufacturers shut down due to a labor shortage, along with mass production shutdowns and supply chain disruptions. The high reliance on home-prepared vegetarian food as a result of the COVID-19 virus fear and the lockdown that prevented people from leaving their homes are a couple of the other factors that contributed to the decline in sales of feed anticoccidial during the pandemic.
Due to the presence of coccidia, one of the more common parasitic diseases in poultry is the use of antibiotics. Therefore, the poultry segment is expected to register the largest share during the forecast period. As a result of co-limiting the coccidia, this infectious infection develops in the intestine. Coccidial poisoning can have a significant negative impact on poultry, and it has the potential to economically disrupt the poultry industry. For this reason, it is crucial to put in place the proper controls to stop any coccidial poisoning. The main requirements to stop coccidiosis in poultry are vaccination campaigns and the use of anti-coccidiotic medications for both prophylaxis and treatment.
During the forecast period, the salinomycin segment is expected to witness lucrative growth. Salinomycin is an antibiotic that is a monocarboxylic polyether and is produced when Streptomyces albus ferments. Salinomycin's primary mechanism of action involves ionophoric activity, primarily through the binding of monovalent cations like potassium, sodium, rubidium, and lithium, which are then channeled into livestock cells in a complex manner. It is the fastest-growing market segment globally due to its lower cost compared to other anticoccidials and easy availability.
Owing to the enormous number of domesticated animals in the region, Asia Pacific is expected to witness the largest share over the forecast period. Due to factors like rising health spending, particularly in India and China, and growing awareness of animal health over the past few years, the animal healthcare market in Asia Pacific has undergone significant changes. Significant increases in livestock breeding for the production of meat and poultry were also observed in China and India. Livestock producers are putting more emphasis on animal healthcare and overusing livestock antibiotics, such as anticoccidials, to satisfy the rising demand for milk and meat products. Such elements are accelerating the growth in this area.
During the forecast period, North America is anticipated to register the highest growth rate. The market's need in this area is being driven by an increase in the need to guarantee the quality of poultry products and an increase in production rates. Moreover, the government's increasing investments in pharmaceutical firms also broaden the market's demand. Following the United States in capturing the largest market share is Canada. One of the main drivers of market expansion in this nation is the expansion of the livestock population. The increasing demand for high-quality meat products is credited with accelerating the market's growth rate in this region.
Some of the key players profiled in the Feed Anticoccidials Market include: Bioproperties Pty. Ltd., Ceva Animal Health, Elanco Animal Health, Huvepharma, Impextraco, Kemin Industries, Merck Animal Health, Phibro Animal Health, Qilu Animal Health Products Co. Ltd., Virbac S.A, Zydus Animal Health and Zoetis.
In February 2023, Elanco Animal Health announces the addition of PenPoint™ Sort to help cattle feeders maximize profitability. PenPoint Sort adds to the existing Elanco Knowledge Solutions portfolio of services designed to optimize practices and products through trusted tools, technologies and insights to empower data-driven decision making.
In February 2023, Elanco Animal Health announced the U.S. Food and Drug Administration (FDA) approved Bexacat™ (bexagliflozin tablets), the first orally administered prescription medication to improve glycemic control in cats with diabetes mellitus, expanding Elanco's innovative feline portfolio while addressing an unmet need for this chronic condition in adult cats.
In December 2022, Ceva Sante Animale (Ceva) announces the acquisition of the Argentinian companies Zoovet - specialized in the production and marketing of animal health products and Biotecnofe - a biotech start-up developing innovative products to be distributed by Zoovet.
All the customers of this report will be entitled to receive one of the following free customization options: